A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants

Phase 1 Completed 8 enrolled Eisai Inc.

NaSingle-groupOpen-labelTreatment

Summary

The primary objective of the study is to achieve mass balance recovery of \[14C\]-radiolabel in urine and feces and to identify and quantify the main elimination pathways of E2027.

Timeline

Start: 2019-07-18
Primary completion: 2019-10-11
Completion: 2019-10-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irsenontrine	Small molecule	50 mg	Oral

A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants

Summary

Timeline

Drugs

Indications